Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
  • Policy / Pricing

CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices

FDA

CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III

Policy / PricingRead full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

FDA

CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III

Policy / PricingRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters
Next: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

Related Stories

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • Policy / Pricing

SCOTUS won’t hear pharma’s IRA complaints

pharminent May 19, 2026
  • Policy / Pricing

Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019

pharminent May 18, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.